从薪酬分布看，A股体外诊断公司CFO年薪平均值为84.47万元。经统计，处于50万以下、50万-100万、 100万-200万、200万以上各区间的人数占比分别为10%、76%、10%、4%。 其中，年薪排行前三的CFO分别为新产业的丁晨柳、万孚生物的余芳霞、科华生物的罗芳，三人年薪分 别为284万元、178.17万元、161.48万元。 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有29家上市体外诊断公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到66%；50岁以上的CFO占比 为34%。其中，目前仍任职的最年轻的上市公司CFO年龄41岁，为硕世生物的孟元元。 从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为4%、52%、41%、3%。其 中，获得博士学历的CF ...

Core Insights - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - The CFO age distribution shows that 66% are aged between 40 and 50, while 34% are over 50 [1] - The educational background of CFOs indicates that 52% hold a bachelor's degree, 41% a master's degree, and only 3% a doctoral degree [1] Salary Distribution - The average annual salary for CFOs in the A-share diagnostic companies is 844,700 yuan [1] - Salary distribution reveals that 10% earn below 500,000 yuan, 76% earn between 500,000 and 1 million yuan, 10% earn between 1 million and 2 million yuan, and 4% earn above 2 million yuan [1] - The top three highest-paid CFOs are Ding Chenliu from New Industry at 2.84 million yuan, Yu Fangxia from Wanfu Biology at 1.78 million yuan, and Luo Fang from Kehua Biology at 1.61 million yuan [2] Salary Changes - The largest salary decrease was observed for Yu Jinhong from Dongfang Biology, with a year-on-year decline of 30.36% [2] - The highest salary increase was recorded for Li Songtao from Tengkang Life, with a year-on-year increase of 70.65% [2]

Market Overview - The Shanghai Composite Index is at 3636.69 points, slightly down by 0.08%, with a total trading volume of 802.9 billion yuan [1] - 21 A-shares have surpassed their annual line today, with notable stocks showing significant deviation rates [1] Stocks with Significant Deviation Rates - *ST Yitong has a deviation rate of 2.59%, with a price increase of 4.74% and a turnover rate of 2.93% [1] - Landun Optoelectronics shows a deviation rate of 1.97%, with a price increase of 6.14% and a turnover rate of 10.07% [1] - Guodian Power has a deviation rate of 1.53%, with a price increase of 1.52% and a turnover rate of 0.48% [1] Stocks with Smaller Deviation Rates - Pumen Technology and Jinlang Technology have just crossed the annual line with minor deviation rates of 0.06% and 0.13% respectively [2] - Longi Green Energy has a deviation rate of 0.20%, with a price increase of 0.25% [2]

Industry News - The People's Bank of China has increased its gold reserves for the ninth consecutive month, with reserves reaching 73.96 million ounces (approximately 2300.41 tons) as of the end of July, marking a month-on-month increase of 60,000 ounces (approximately 1.86 tons) [3] - The Ministry of Industry and Information Technology, along with six other departments, has released implementation opinions to promote innovation and development in the brain-computer interface industry, aiming for breakthroughs in key technologies by 2027 [3] - As of August 7, southbound funds have accumulated a net purchase of 894.528 billion Hong Kong dollars this year, exceeding the total for the entire year of 2024 by 111%, setting a new historical high [3] - The world's first fully integrated intelligent robot 4S store, Robot Mall, is set to officially open on August 8, providing functions similar to traditional car 4S stores, including sales, parts supply, after-sales service, and information feedback [3] Company News - Upwind New Materials announced a net profit of 29.9004 million yuan for the first half of the year, a year-on-year decrease of 32.91% [6] - SMIC reported second-quarter revenue of 2.21 billion USD, a year-on-year increase of 16%, and expects third-quarter revenue to grow by 5% to 7% quarter-on-quarter, with a gross margin between 18% and 20% [6] - Seres announced that its new energy vehicle sales in July reached 44,581 units, a year-on-year increase of 5.7% [12] - China Mobile reported a net profit of 84.2 billion yuan for the first half of the year, with an interim dividend of 2.75 Hong Kong dollars per share [12]

【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不 对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担 全部责任。邮箱：news_center@staff.hexun.com 格隆汇8月7日丨东方生物(688298.SH)在互动平台表示，公司现阶段基孔肯雅热检测试剂有抗原检测试 剂、抗体IgM/IgG检测试剂和核酸检测试剂，主要销往非洲、南美、东南亚、南亚等地区，其他区域或 国家根据取证情况积极争取。 ...

东方生物（688298.SH）8月7日在投资者互动平台表示，公司现阶段基孔肯雅热检测试剂有抗原检测试 剂、抗体IgM/IgG检测试剂和核酸检测试剂，主要销往非洲、南美、东南亚、南亚等地区，其他区域或 国家根据取证情况积极争取。 每经AI快讯，有投资者在投资者互动平台提问：公司基孔肯雅热的检测试剂目前有订单吗？主要销往 哪些地区？ （文章来源：每日经济新闻） ...

Core Insights - The company, Dongfang Biological (688298.SH), announced the acquisition of several medical device registration certificates, including inflammation marker detection kits and COVID-19/FluA&B antigen combination test kits [1] Group 1: Product Development - The certification of the inflammation marker detection kit enhances the company's product lineup in the domestic inflammation indicator detection field [1] - The new products expand the application areas of the flow cytometry technology platform, benefiting the overall market expansion in China [1] Group 2: International Market Expansion - The company has obtained self-test certificates for respiratory detection, drug detection, and tumor marker detection products in key international markets such as the United States, the United Kingdom, and Thailand [1] - This expansion enriches the variety of products and testing applications in core international markets, facilitating growth in these regions [1]

Group 1 - The company Zhejiang Oriental Gene Biological Products Co., Ltd. has approved a share repurchase plan to maintain company value and shareholder rights, with a maximum repurchase price of RMB 32.44 per share and a total repurchase amount between RMB 25 million and RMB 50 million [2][3] - As of July 31, 2025, the company has repurchased a total of 234,591 shares, accounting for 0.1164% of the total share capital, with a total payment of RMB 6.812262 million [3][4] Group 2 - The company and its subsidiaries have obtained several medical device registration certificates, enhancing its product series in the domestic inflammation indicator detection field and expanding the application of its flow cytometry technology platform [6][7] - The company has also achieved major product self-testing certifications in the United States, the United Kingdom, and Thailand, which will help expand its market presence in these key regions [7]

证券代码：688298 证券简称：东方生物 公告编号：2025-036 浙江东方基因生物制品股份有限公司 关于以集中竞价交易方式回购公司股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江东方基因生物制品股份有限公司（以下简称"公司"）于 2025 年 6 月 26 日召开第三届董事会第十三次会议，审议通过了《关于以集中竞价交易方式回购 公司股份的方案》，同意公司以自有资金或自筹资金（含股票回购专项贷款资金等） 通过上海证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币 普通股（A 股）股票，本次回购的股份将用于维护公司价值及股东权益，回购价格 不超过人民币 32.44 元/股（含），回购资金总额不低于人民币 2,500.00 万元（含）， 不超过人民币 5,000.00 万元（含），回购期限自董事会审议通过本次股份回购方案 之日起不超过 3 个月。本次回购的股份将在公司披露回购结果暨股份变动公告 12 个月后采用集中竞价交易方式出售，并在 3 年内完成出售。具体内容详见公司于 20 ...

证券代码：688298 证券简称：东方生物 公告编号：2025-037 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 三、境外合作取得医疗器械注册证基本情况如下： | 产品名称 | 适用国家 及证书编 | 证书类 | 预期用途 | 有效期 | 持证 | | --- | --- | --- | --- | --- | --- | | | 号 | 型 | | | 公司 | | Healgen Rapid Check | | | 本产品拟用于直接从个体鼻 | | | | COVID-19/Flu A&B Antigen Test | 68-2-2-1-000 | 泰国医疗 | | 至 | 东方 | | 衡健新冠、甲乙流抗原联合检测 | | | 拭子标本中定性和快速鉴别 | | | | | 7059 | 器械证书 | | 2029/12/31 | 生物 | | 试剂（自测） | | | 检测新冠、甲乙流抗原。 | | | 四、对上市公司的影响 公司炎症标志物 ...